Sökning: WFRF:(Hankey Graeme) > Characterization of...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06394naa a2200913 4500 | |
001 | oai:lup.lub.lu.se:71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e | |
003 | SwePub | |
008 | 180323s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e2 URI |
024 | 7 | a https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.0272 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Kasner, Scott E.u University of Pennsylvania4 aut |
245 | 1 0 | a Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial |
264 | 1 | b Elsevier BV,c 2018 |
520 | a Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS. Aims: We aimed to describe the baseline characteristics of this large ESUS cohort to explore relationships among key subgroups. Methods: We enrolled 7213 patients at 459 sites in 31 countries. Prespecified subgroups for primary safety and efficacy analyses included age, sex, race, global region, stroke or transient ischemic attack prior to qualifying event, time to randomization, hypertension, and diabetes mellitus. Results: Mean age was 66.9 ± 9.8 years; 24% were under 60 years. Older patients had more hypertension, coronary disease, and cancer. Strokes in older subjects were more frequently cortical and accompanied by radiographic evidence of prior infarction. Women comprised 38% of participants and were older than men. Patients from East Asia were oldest whereas those from Latin America were youngest. Patients in the Americas more frequently were on aspirin prior to the qualifying stroke. Acute cortical infarction was more common in the United States, Canada, and Western Europe, whereas prior radiographic infarctions were most common in East Asia. Approximately forty-five percent of subjects were enrolled within 30 days of the qualifying stroke, with earliest enrollments in Asia and Eastern Europe. Conclusions: NAVIGATE-ESUS is the largest randomized trial comparing antithrombotic strategies for secondary stroke prevention in patients with ESUS. The study population encompasses a broad array of patients across multiple continents and these subgroups provide ample opportunities for future research. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a Aspirin | |
653 | a Cerebral embolism | |
653 | a Cryptogenic stroke | |
653 | a Embolic Stroke of Undetermined Source (ESUS) | |
653 | a Randomized trial | |
653 | a Rivaroxaban | |
653 | a Stroke | |
653 | a Stroke prevention | |
700 | 1 | a Lavados, Pablou University of Chile4 aut |
700 | 1 | a Sharma, Mukulu McMaster University4 aut |
700 | 1 | a Wang, Yongjunu Capital University of Medical Sciences4 aut |
700 | 1 | a Wang, Yilongu Capital University of Medical Sciences4 aut |
700 | 1 | a Dávalos, Antoniu Hospital Universitari Germans Trias i Pujol4 aut |
700 | 1 | a Shamalov, Nikolayu Pirogov Russian National Research Medical University (RNRMU)4 aut |
700 | 1 | a Cunha, Luisu University Hospital of Coimbra4 aut |
700 | 1 | a Lindgren, Arneu Lund University,Lunds universitet,Klinisk strokeforskning,Forskargrupper vid Lunds universitet,Clinical Stroke Research Group,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)neur-ali |
700 | 1 | a Mikulik, Robertu St. Anne's University Hospital Brno4 aut |
700 | 1 | a Arauz, Antoniou Instituto Nacional de Neurología y Neurocirugía4 aut |
700 | 1 | a Lang, Wilfried4 aut |
700 | 1 | a Czlonkowska, Annau Medical University of Warsaw4 aut |
700 | 1 | a Eckstein, Jensu University Hospital Basel4 aut |
700 | 1 | a Gagliardi, Rubens4 aut |
700 | 1 | a Amarenco, Pierreu Hopital Bichat-Claude-Bernard AP-HP4 aut |
700 | 1 | a Ameriso, Sebastián F.4 aut |
700 | 1 | a Tatlisumak, Turgutu Helsinki University Central Hospital4 aut |
700 | 1 | a Veltkamp, Rolandu Imperial College London4 aut |
700 | 1 | a Hankey, Graeme J.u University of Western Australia, Crawley4 aut |
700 | 1 | a Toni, Danilo S.u Sapienza University of Rome4 aut |
700 | 1 | a Bereczki, Danielu Semmelweis University4 aut |
700 | 1 | a Uchiyama, Shinichirou Sanno Hospital4 aut |
700 | 1 | a Ntaios, George4 aut |
700 | 1 | a Yoon, Byung Woou Seoul National University Hospital4 aut |
700 | 1 | a Brouns, Raf4 aut |
700 | 1 | a DeVries Basson, M. M.u Tiervlei Trial Centre4 aut |
700 | 1 | a Endres, Matthiasu Charité - University Medicine Berlin4 aut |
700 | 1 | a Muir, Keithu University of Glasgow4 aut |
700 | 1 | a Bornstein, Natan4 aut |
700 | 1 | a Ozturk, Serefnur4 aut |
700 | 1 | a O'Donnell, Martinu National University of Ireland Galway4 aut |
700 | 1 | a Mundl, Hardiu Bayer Pharma AG4 aut |
700 | 1 | a Pater, Calin4 aut |
700 | 1 | a Weitz, Jeffrey4 aut |
700 | 1 | a Peacock, W. Franku Baylor College of Medicine4 aut |
700 | 1 | a Swaminathan, Balakumaru Population Health Research Institute, Ontario4 aut |
700 | 1 | a Kirsch, Bodou Bayer Pharma AG4 aut |
700 | 1 | a Berkowitz, Scott D.u Bayer Corporation, USA4 aut |
700 | 1 | a Peters, Garyu Janssen Pharmaceuticals, US4 aut |
700 | 1 | a Pare, Guillaume4 aut |
700 | 1 | a Themeles, Ellisonu University of Pennsylvania4 aut |
700 | 1 | a Shoamanesh, Ashkan4 aut |
700 | 1 | a Connolly, Stuart J.4 aut |
700 | 1 | a Hart, Robert G.u University of Pennsylvania4 aut |
710 | 2 | a University of Pennsylvaniab University of Chile4 org |
773 | 0 | t Journal of Stroke and Cerebrovascular Diseasesd : Elsevier BVg 27:6, s. 1673-1682q 27:6<1673-1682x 1052-3057 |
856 | 4 | u http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.027y FULLTEXT |
856 | 4 | u https://helda.helsinki.fi/bitstream/10138/302414/1/1_s2.0_S1052305718300430_main.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e |
856 | 4 8 | u https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.027 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.